AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30801390 — intervention group
Group type: COMPARATOR
Intervention: Carter-Thomason CloseSure System (CT)
Number of subjects: 0
Study 28953989 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model (CCM)
Number of subjects: 114
Study 28953989 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 114
Study 25070538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 40
Study 25070538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23641793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin 500 mg 1*1 for 21 days
Number of subjects: 140
Study 23641793 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 140
Study 17218327 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy plus ultrasound (US)
Number of subjects: 221
Study 17218327 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy plus placebo ultrasound (placebo US)
Number of subjects: 221
Study 15234509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with adrenaline (1:200,000)
Number of subjects: 21
Study 15234509 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine buffered with 8.4% NaHCO3 at a 5:1 ratio
Number of subjects: 21
Study 11145762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (biventricular pacing)
Number of subjects: 500
Study 9178343 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects described as likely to respond to suggestion
Number of subjects: 30
Study 9178343 — intervention group
Group type: COMPARATOR
Intervention: Subjects described as unlikely to respond to suggestion
Number of subjects: 30
Study 8240146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline infusion adjusted to maintain therapeutic levels.
Number of subjects: 59
Study 8240146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 59
Study 8240146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received nebulised salbutamol and ipratropium bromide, intravenous hydrocortisone, and oxygen.
Number of subjects: 59
Study 3927692 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (150 mg/day in 3 daily doses) for 4 weeks
Number of subjects: 12
Study 30880943 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine BDP/FF/G
Number of subjects: 0
Study 27913870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga (HY)
Number of subjects: 83
Study 27913870 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic/strengthening exercises (ASE)
Number of subjects: 83
Study 27913870 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 83
Study 26681678 — intervention group
Group type: EXPERIMENTAL
Intervention: trabectedin 1.3 mg/mq i.v. q 3 weeks
Number of subjects: 100
Study 24438360 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 38
Study 24438360 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisodium citrate
Number of subjects: 38
Study 24438360 — intervention group
Group type: EXPERIMENTAL
Intervention: No anticoagulation
Number of subjects: 38
Study 22099522 — intervention group
Group type: EXPERIMENTAL
Intervention: Early neurodevelopmental intervention
Number of subjects: 201
Study 22099522 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 201
Study 19204201 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/Cyclophosphamide (TC)
Number of subjects: 1016
Study 19204201 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin/Cyclophosphamide (AC)
Number of subjects: 1016
Study 17549328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular stimulation
Number of subjects: 43
Study 17549328 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine injection
Number of subjects: 43
Study 15308432 — intervention group
Group type: EXPERIMENTAL
Intervention: Antianginal medications (beta-blockers, calcium antagonists, long-acting nitrates)
Number of subjects: 7038
Study 15308432 — intervention group
Group type: EXPERIMENTAL
Intervention: Antianginal medications prescribed
Number of subjects: 7038
Study 11551104 — intervention group
Group type: COMPARATOR
Intervention: 35delG mutation screening in GJB2 gene
Number of subjects: 4123
Study 9842806 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 4% (n = 31)
Number of subjects: 60
Study 9842806 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion 100 microg kg(‐1) min(‐1) (n = 29)
Number of subjects: 60
Study 8131635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/day)
Number of subjects: 46
Study 8131635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 10303909 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look laparotomy
Number of subjects: 0
Study 10303909 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 162672 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen (900‐1800 mg/day)
Number of subjects: 218
Study 162672 — intervention group
Group type: COMPARATOR
Intervention: indomethacin (75‐150 mg/day)
Number of subjects: 218
Study 162672 — intervention group
Group type: COMPARATOR
Intervention: indomethacin
Number of subjects: 218
Study 162672 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen
Number of subjects: 218
Study 31233885 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT combined with limited excision
Number of subjects: 8
Study 28151896 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Gastrectomy (DG)
Number of subjects: 1262
Study 28151896 — intervention group
Group type: COMPARATOR
Intervention: Total Gastrectomy (TG)
Number of subjects: 1262
Study 26036903 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome paper
Number of subjects: 0
Study 26036903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancillary publications utilizing specimens from the repository
Number of subjects: 0
Study 26036903 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline paper and secondary hypotheses papers
Number of subjects: 0
Study 23771607 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO-coupled movements
Number of subjects: 0
Study 23771607 — intervention group
Group type: EXPERIMENTAL
Intervention: ANTI-coupled movements
Number of subjects: 0
Study 21372745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 110
Study 21372745 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 110
Study 19013758 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 16-week home-based hand exercise
Number of subjects: 46
Study 19013758 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 46
Study 16625231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5‐1 mg weekly for 6 months)
Number of subjects: 402
Study 16625231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 16625231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 402
Study 15043534 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.2%
Number of subjects: 33
Study 15043534 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone 0.15%
Number of subjects: 33
Study 11769817 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 6 mg
Number of subjects: 15
Study 11769817 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 3 mg
Number of subjects: 15
Study 11769817 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 15
Study 11769817 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 3 mg and 6 mg
Number of subjects: 15
Study 9231677 — intervention group
Group type: COMPARATOR
Intervention: External irradiation alone (planned dose 60 Gy)
Number of subjects: 98
Study 9231677 — intervention group
Group type: EXPERIMENTAL
Intervention: External irradiation plus additional HDR brachytherapy (4.8 Gy each)
Number of subjects: 98
Study 8220800 — intervention group
Group type: EXPERIMENTAL
Intervention: Open challenge with a mixture of food preservatives, colourings and flavours (fizzy lemonade)
Number of subjects: 271
Study 8220800 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled challenge with gelatine capsules
Number of subjects: 271
Study 3690941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 120
Study 3690941 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg codeine
Number of subjects: 120
Study 3690941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen plus 60 mg codeine
Number of subjects: 120
Study 3690941 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 30355362 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOF2
Number of subjects: 24
Study 30355362 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 24
Study 30355362 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 24
Study 26996315 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS (intermittent Theta Burst Stimulation) over the left PFC (F3)
Number of subjects: 41
Study 26996315 — intervention group
Group type: COMPARATOR
Intervention: Sham-controlled activating protocol
Number of subjects: 41
Study 24342152 — intervention group
Group type: EXPERIMENTAL
Intervention: HMS (hemostasis management system) measurements
Number of subjects: 38
Study 24342152 — intervention group
Group type: COMPARATOR
Intervention: ACT (activated coagulation time) based management
Number of subjects: 38
Study 22898215 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg every other week for 12 weeks)
Number of subjects: 46
Study 22898215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 21116022 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 long-chain polyunsaturated fatty acids (LCPUFA) supplementation (600 mg EPA and 400 mg DHA)
Number of subjects: 0
Study 21116022 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 long-chain polyunsaturated fatty acids (LCPUFA) supplementation
Number of subjects: 0
Study 21116022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18175744 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic-index diet
Number of subjects: 162
Study 18175744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diet
Number of subjects: 162
Study 18175744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-monounsaturated-fat diet
Number of subjects: 162
Study 15674155 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard parenteral antibiotics for 2 weeks followed by oral antibiotics for 4 weeks (Group I)
Number of subjects: 23
Study 15674155 — intervention group
Group type: COMPARATOR
Intervention: Local gentamicin‐polymethylmethacrylate bead implantation (Group II)
Number of subjects: 23
Study 12646232 — intervention group
Group type: EXPERIMENTAL
Intervention: sn-1,3-diacylglycerol (DAG)
Number of subjects: 49
Study 12646232 — intervention group
Group type: COMPARATOR
Intervention: triacylglycerol (TAG)
Number of subjects: 49
Study 10765510 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel in the morning
Number of subjects: 126
Study 10765510 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel in the evening
Number of subjects: 126
Study 8774203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ardeparin (low-molecular-weight heparin), 0.005 mL/kg (50 anti-Xa U/Kg), administered subcutaneously twice daily for 14 days or until discharge.
Number of subjects: 246
Study 8774203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (graduated compression stockings alone), administered subcutaneously twice daily for 14 days or until discharge.
Number of subjects: 246
Study 8774203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ardeparin (low-molecular-weight heparin)
Number of subjects: 246
Study 8774203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (graduated compression stockings alone)
Number of subjects: 246
Study 1354372 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold masking release for gap detection in conditions resulting in CMR
Number of subjects: 0
Study 1354372 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold masking release for gap detection in conditions not resulting in CMR
Number of subjects: 0
Study 1354372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of stimulation
Number of subjects: 0
Study 6338868 — intervention group
Group type: EXPERIMENTAL
Intervention: 4',6-Dichloroflavan (1 mg/kg, 3 times per day for 3 doses before and 13 doses after challenge)
Number of subjects: 63
Study 6338868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 63
Study 31803478 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced HUNT model
Number of subjects: 4051
Study 31803478 — intervention group
Group type: COMPARATOR
Intervention: NLST criteria
Number of subjects: 4051
Study 31803478 — intervention group
Group type: COMPARATOR
Intervention: NELSON criteria
Number of subjects: 4051
Study 29036621 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-neck postoperative radiotherapy
Number of subjects: 275
Study 29036621 — intervention group
Group type: COMPARATOR
Intervention: Limited field postoperative radiotherapy
Number of subjects: 275
Study 25549767 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning-focused cognitive behavioral therapy (CBT)
Number of subjects: 159
Study 25549767 — intervention group
Group type: COMPARATOR
Intervention: Solution-focused treatment (SFT)
Number of subjects: 159
Study 25549767 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning-focused CBT
Number of subjects: 159
Study 23307206 — intervention group
Group type: EXPERIMENTAL
Intervention: InflammaDry
Number of subjects: 206
Study 23307206 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment
Number of subjects: 206
Study 21816474 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-parent psychotherapy (CPP)
Number of subjects: 75
Study 21816474 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (monthly case management plus referrals to community services)
Number of subjects: 75
Study 18070948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled ablation (open irrigation at 15 ml/min, 45 degrees C, 35 (5) W)
Number of subjects: 36
Study 18070948 — intervention group
Group type: COMPARATOR
Intervention: Standard temperature-controlled 4 mm tip catheter ablation (55 degrees C, 35 (5) W)
Number of subjects: 36
Study 18070948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled ablation
Number of subjects: 36
Study 18070948 — intervention group
Group type: COMPARATOR
Intervention: Standard temperature-controlled 4 mm tip catheter ablation
Number of subjects: 36
Study 16773453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 9
Study 16773453 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone butyrate ointment
Number of subjects: 9
Study 12373659 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 1,800 mg/day)
Number of subjects: 0
Study 12373659 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 10228111 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microgram/d for 8 days)
Number of subjects: 9
Study 10228111 — intervention group
Group type: COMPARATOR
Intervention: Allergen inhalation
Number of subjects: 9
Study 7671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exercise with 2510-kJ meal
Number of subjects: 2
Study 7671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exercise with 5020-kJ meal
Number of subjects: 2
Study 7671879 — intervention group
Group type: COMPARATOR
Intervention: Control with 2510-kJ meal
Number of subjects: 2
Study 7671879 — intervention group
Group type: COMPARATOR
Intervention: Control with 5020-kJ meal
Number of subjects: 2
Study 7671879 — intervention group
Group type: EXPERIMENTAL
Intervention: 5020-kJ meal in two portions after exercise
Number of subjects: 2
Study 7671879 — intervention group
Group type: EXPERIMENTAL
Intervention: 5020-kJ meal in one portion after exercise
Number of subjects: 2
Study 7671879 — intervention group
Group type: EXPERIMENTAL
Intervention: First portion of 2510-kJ meal
Number of subjects: 2
Study 7671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Second portion of 2510-kJ meal
Number of subjects: 2
Study 2402214 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine supplementation (6,000 mg.d‐1 for 2 d)
Number of subjects: 9
Study 2402214 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study 7446607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine irrigation with cefamandole nafate solution
Number of subjects: 90
Study 7446607 — intervention group
Group type: COMPARATOR
Intervention: Irrigation with normal saline solution
Number of subjects: 90
Study 7446607 — intervention group
Group type: COMPARATOR
Intervention: No irrigation
Number of subjects: 90
Study 6342564 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 46
Study 6342564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31017869 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) score
Number of subjects: 294
Study 31017869 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal aerobic capacity (VO2max)
Number of subjects: 294
Study 31017869 — intervention group
Group type: COMPARATOR
Intervention: BMI and age correlation
Number of subjects: 294
Study 31017869 — intervention group
Group type: COMPARATOR
Intervention: BMI and VO2max correlation
Number of subjects: 294
Study 31017869 — intervention group
Group type: COMPARATOR
Intervention: BMI and total PA score correlation
Number of subjects: 294
Study 30540834 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal experience
Number of subjects: 1030
Study 30540834 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading online content
Number of subjects: 1030
Study 30540834 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching visual media online
Number of subjects: 1030
Study 30540834 — intervention group
Group type: EXPERIMENTAL
Intervention: Science organizations
Number of subjects: 1030
Study 30540834 — intervention group
Group type: EXPERIMENTAL
Intervention: Universities
Number of subjects: 1030
Study 30540834 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends/family
Number of subjects: 1030
Study 30540834 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics (education level, age)
Number of subjects: 1030
Study 30540834 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics (education, race, age, size of residence)
Number of subjects: 1030
Study 26860124 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar monotherapy
Number of subjects: 0
Study 24638865 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (abnormal clinical presentation)
Number of subjects: 236
Study 24638865 — intervention group
Group type: COMPARATOR
Intervention: Group B (clinically typical nevi)
Number of subjects: 236
Study 22813609 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride
Number of subjects: 57
Study 20412603 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuits fortified with vitamin A at 30% of the RDA once a day for 9 months
Number of subjects: 580
Study 20412603 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuits fortified with vitamin A at 100% of the RDA once a day for 3 months
Number of subjects: 580
Study 20412603 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuits containing 20,000 IU of vitamin A once a week for 3 months
Number of subjects: 580
Study 20412603 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 200,000 IU vitamin A capsule administration
Number of subjects: 580
Study 19227864 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy containing a specialized product enriched with vitamins and minerals (50% calcium, 20% protein, 17-60% of 11 minerals, and 11 vitamins)
Number of subjects: 0
Study 15704058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (500 mg twice daily, titrated slowly or rapidly)
Number of subjects: 370
Study 15704058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 370
Study 15704058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 15846939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuban trivalent inactivated vaccine against human leptospirosis (vax‐SPIRAL)
Number of subjects: 0
Study 15846939 — intervention group
Group type: COMPARATOR
Intervention: Russian-made vaccine
Number of subjects: 0
Study 10350029 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg during the midluteal phase of the menstrual cycle
Number of subjects: 12
Study 10350029 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam 2 mg during the midfollicular phase of the menstrual cycle
Number of subjects: 12
Study 8622050 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard informed consent procedures plus a supplementary, telephone‐based contact with an oncology nurse
Number of subjects: 180
Study 8622050 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent procedures based on verbal explanations from the treating physician plus written information
Number of subjects: 180
Study 1760833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (ISDN) at a dose of 10 mg/h over the first 3 days of infarction
Number of subjects: 115
Study 1760833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 115
Study 1760833 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulants only
Number of subjects: 115
Study 7333402 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen solution
Number of subjects: 8
Study 7333402 — intervention group
Group type: COMPARATOR
Intervention: Commercial solid formulations of 8-methoxypsoralen
Number of subjects: 8
Study 31359271 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of oral risperidone
Number of subjects: 71
Study 31359271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose adjustment of risperidone by -25% for poor metabolizers and by -10% for intermediate metabolizers
Number of subjects: 71